ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, announces that ...
Revolutionising healthcare with peptide-based therapies
ImmuPharma is a biopharmaceutical company that specializes in the usage and development of biopolymers, specifically peptides.
Peptides are naturally occurring biological molecules and represent a distinctive class of pharmaceutical therapeutics, uniquely positioned between small molecules and proteins, yet biochemically and therapeutically distinct from both.
We are dedicated to developing an innovative portfolio of peptide-based therapeutic drugs with a focus on Autoimmunity/Inflammation and Anti-Infectives.
In summary:
- Developing clinical programs for P140 in Phase 3 for Systemic Lupus Erythematosus (SLE) (Lupuzor™) and P140 in a pivotal Phase 2/3 for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Advancing preclinical programs using our proprietary technology to program the ADMET properties of peptides, as well as small molecules with bioavailability limitations
- Unlocking value through strategic licensing, partnerships, and collaborations
- Creating near-term shareholder value with our late stage, lead asset, P140 and providing significant opportunities throughout our pipeline
BioPharma: Peptides are naturally occurring biological molecules built from our body’s amino acids. Peptides also represent a unique class of biopharmaceutical therapeutics, molecularly poised between small molecules and proteins, yet biochemically and therapeutically distinct from both. With expertise in peptide innovation, ImmuPharma is focused on delivering safe and efficacious peptide-based Bio-drugs through its Bordeaux subsidiary ImmuPharma Biotech.
Our focus and expertise within R&D are:
Creation: Our principal mission is to craft a targeted and robust pipeline of efficient and safe compounds based on biopolymers: peptides. Our lead candidate, P140 (Lupuzor™), is advancing into Phase 3 for the treatment of systemic lupus erythematosus (SLE), and its unique mechanism of action heralds significant promise for therapeutic repositioning in the realm of autoimmune diseases.
Our team is also intensely focused on therapeutic upcycling, which strives to achieve considerable enhancements in existing therapies for specific diseases. This program leverages our ADMET (Chemical absorption, distribution, metabolism, excretion, and toxicity) programming technology to forge long-term shareholder value.
Evolution: necessitates a drive for positive transformation. Our inspirational and attainable goals include:
• Spearheading innovative R&D, targeted at commercially viable and attainable goals
• Aligning with expert collaborators for the development and commercialisation of our therapeutic products
• Developing a pipeline with depth and breadth to facilitate near and long term value, continuous news flow, and revenue generation
Our pipeline
*Phase 2/3 adaptive trial becomes a pivotal trial for filing
Key progress
Financial, Business and Portfolio Development Update
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased ...
Simbec-Orion appointed as CRO | Decision to move directly into a Phase 3 pivotal study | Compelling findings on P140’s MOA
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased ...
Market Cap
15 minute delayed share price provided by Hemscott Group Limited Disclaimer
Share Price - more details
Market Commentary
